69819-86-9

Upstream product

• 70-18-8 GLUTATHIONE 
• 124-65-2 sodium cacodylate 
• 557-89-1 Dimethylchloroarsine 
• 75-60-5 Dimethylarsinic acid 
• 91919-78-7 cysteinyldimethylthioarsenite 
• 471-35-2 tetramethyldiarsine 

Relevant academic research and scientific papers

Toxicity of a trivalent organic arsenic compound, dimethylarsinous glutathione in a rat liver cell line (TRL 1215)

Background and purpose:Although inorganic arsenite (AsIII) is toxic in humans, it has recently emerged as an effective chemotherapeutic agent for acute promyelocytic leukemia (APL). In humans and most animals, As III is enzymatically methylated in the liver to weakly toxic dimethylarsinic acid (DMAsV) that is a major pentavalent methylarsenic metabolite. Recent reports have indicated that trivalent methylarsenicals are produced through methylation of AsIII and participate in arsenic poisoning. Trivalent methylarsenicals may be generated as arsenical-glutathione conjugates, such as dimethylarsinous glutathione (DMAsIIIG), during the methylation process. However, less information is available on the cytotoxicity of DMAsIIIG.Experimental approach:We synthesized and purified DMAsIIIG using high performance TLC (HPTLC) methods and measured its cytotoxicity in rat liver cell line (TRL 1215 cells).Key results:DMAsIIIG was highly cytotoxic in TRL 1215 cells with a LC50 of 160 nM. We also found that DMAsIIIG molecule itself was not transported efficiently into the cells and was not cytotoxic; however it readily became strongly cytotoxic by dissociating into trivalent dimethylarsenicals and glutathione (GSH). The addition of GSH in micromolar physiological concentrations prevented the breakdown of DMAs IIIG, and the DMAsIIIG-induced cytotoxicity. Physiological concentrations of normal human serum (HS), human serum albumin (HSA), and human red blood cells (HRBC) also reduced both the cytotoxicity and cellular arsenic uptake induced by exposure to DMAsIIIG.Conclusions and implications:These findings suggest that the significant cytotoxicity induced by DMAsIIIG may not be seen in healthy humans, even if DMAs IIIG is formed in the body from AsIII.

Characterization and Mechanistic Study of the Radical SAM Enzyme ArsS Involved in Arsenosugar Biosynthesis

Arsenosugars are a group of arsenic-containing ribosides that are found predominantly in marine algae but also in terrestrial organisms. It has been proposed that arsenosugar biosynthesis involves a key intermediate 5′-deoxy-5′-dimethylarsinoyl-adenosine (DDMAA), but how DDMAA is produced remains elusive. Now, we report characterization of ArsS as a DDMAA synthase, which catalyzes a radical S-adenosylmethionine (SAM)-mediated alkylation (adenosylation) of dimethylarsenite (DMAsIII) to produce DDMAA. This radical-mediated reaction is redox neutral, and multiple turnover can be achieved without external reductant. Phylogenomic and biochemical analyses revealed that DDMAA synthases are widespread in distinct bacterial phyla with similar catalytic efficiencies; these enzymes likely originated from cyanobacteria. This study reveals a key step in arsenosugar biosynthesis and also a new paradigm in radical SAM chemistry, highlighting the catalytic diversity of this superfamily of enzymes.

COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER

The present invention relates generally to the field of anti-cancer therapy. More particularly, it provides novel crystalline forms of organic arsenic compounds and methods for their use in treating cancers such as leukemia and solid tumors. Specifically, a crystalline form of darinaparsin, wherein the crystalline form has a melting point in the range of about 190-200 deg C.

Facile dimethylarsenic exchange and pyramidal inversion in its cysteine and glutathione adducts

Rapid thiolate exchange of dimethylarsonium, Me2As+, is observed between two different thiolate species in solution. NMR is used to characterize the equilibrium constants for interthiol transfer as well the rapid intra molecular conf

ORGANOARSENIC COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER

A method for treating a lymphoma selected from non-Hodgkin's and Hodgkin's lymphoma comprising administering an organoarsenic compound having a structure of the formula (I) wherein X is S or Se and R1 and R2 are independently C1-30alkyl(R3, R3′, R4, R5, W and “n” are as defined in claim 1) in particular where the compound is S-dimethylarsinoglutathione, N-(2-S-dimethylarsinothiopropionyl)glycine, 2-amino-3-(dimethylarsino)thio-3-methylbutanoic acid, S-dimethylarsino-thiosuccinic acid or S-dipropylarsino-1-thioglycerol.

COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER

The present invention provides methods of synthesizing organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.

Compounds and methods for the treatment of cancer

The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.

COMPOUNDS AND METHODS FOR TREATMENT OF CANCER

The present invention provides organic arsenicals. Many of these compounds have potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia.

S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer

Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into orga